These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7699031)

  • 1. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
    Sutton LD; Jones RN
    J Clin Microbiol; 1995 Jan; 33(1):146-8. PubMed ID: 7699031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):199-201. PubMed ID: 9401813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.
    Barry AL; Fuchs PC; Allen SD; Jorgensen JH; Tenover FC; Murray PR; Hardy DJ; Baker CN
    J Clin Microbiol; 1993 Sep; 31(9):2375-80. PubMed ID: 8408559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG; Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
    Drugeon HB; Juvin ME; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.
    Cormican MG; Jones RN
    J Clin Microbiol; 1995 Jan; 33(1):215-6. PubMed ID: 7699045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoroquinolone susceptibility testing of Salmonella enterica: detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin.
    Sjölund-Karlsson M; Howie RL; Crump JA; Whichard JM
    J Clin Microbiol; 2014 Mar; 52(3):877-84. PubMed ID: 24391204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
    Jones RN; Johnson DM
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1633-9. PubMed ID: 8807053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
    Cormican MG; Jones RN
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):227-30. PubMed ID: 7554807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
    Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin.
    Dabernat H
    Int J Antimicrob Agents; 1999 Feb; 11(2):139-43. PubMed ID: 10221417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of quinolone-resistant Neisseria gonorrhoeae.
    Kam KM; Wong PW; Cheung MM; Ho NK
    J Clin Microbiol; 1996 Jun; 34(6):1462-4. PubMed ID: 8735098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
    Knapp JS; Hale JA; Neal SW; Wintersheid K; Rice RJ; Whittington WL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
    Isenberg HD; Alperstein P; France K
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.